Understanding Peptide Synthesis: SPPS, Fmoc Chemistry, and Manufacturing Quality

How Peptides Are Made

Understanding how research peptides are manufactured is essential for evaluating quality, interpreting analytical data, and appreciating why certain impurities appear in Certificates of Analysis. The dominant manufacturing method for research peptides is solid-phase peptide synthesis (SPPS), a technique invented by Robert Bruce Merrifield in 1963 — a breakthrough that earned him the Nobel Prize in Chemistry in 1984.

SPPS revolutionized peptide chemistry by enabling the synthesis of peptides on an insoluble solid support (resin), which dramatically simplified the purification of intermediates and made it possible to synthesize peptides that were previously inaccessible.

Solid-Phase Peptide Synthesis (SPPS): The Core Method

The Principle

In SPPS, the peptide is assembled one amino acid at a time while attached to an insoluble resin bead. The C-terminal amino acid is anchored to the resin first, and subsequent amino acids are added sequentially from C-terminus to N-terminus (the reverse of biological protein synthesis, which proceeds N→C).

The key advantage: because the growing peptide chain is attached to a solid support, reagents and byproducts can be washed away simply by filtering the resin — no complex purification is needed between each coupling step.

The SPPS Cycle

Each amino acid addition follows a repeating four-step cycle:

Step 1: Deprotection Remove the temporary protecting group from the N-terminal amine of the resin-bound peptide, exposing a free amine ready for the next coupling reaction.

Step 2: Activation Activate the incoming amino acid’s carboxyl group to make it reactive toward the exposed amine. This is done using coupling reagents (HBTU, HATU, DIC/Oxyma, or similar).

Step 3: Coupling The activated amino acid reacts with the free amine on the resin-bound peptide, forming a new peptide bond. This reaction should ideally go to >99.5% completion.

Step 4: Washing Wash the resin extensively with solvent (typically DMF or NMP) to remove excess reagents, byproducts, and unreacted amino acid.

This cycle is repeated for each amino acid in the sequence. For a 30-amino-acid peptide, the entire cycle is performed 29 times (the first amino acid is loaded onto the resin separately).

Final Steps: Cleavage and Deprotection

After the complete sequence is assembled:

Global deprotection and cleavage: The peptide is cleaved from the resin and all permanent side-chain protecting groups are removed simultaneously. For Fmoc SPPS, this is done with a cleavage cocktail based on trifluoroacetic acid (TFA), typically with scavengers (triisopropylsilane, water, EDT) to quench reactive intermediates.
Precipitation: The crude peptide is precipitated in cold diethyl ether, collected by filtration, and dried.
Purification: The crude peptide (typically 50-85% purity) is purified by preparative HPLC.
Lyophilization: The purified peptide is freeze-dried to a stable powder.

Fmoc vs. Boc Chemistry

Two main protecting group strategies are used in SPPS:

Fmoc (9-Fluorenylmethyloxycarbonyl) Chemistry

Fmoc is the dominant method for modern peptide synthesis. The Fmoc group protects the alpha-amine during coupling and is removed with piperidine (a mild base) in DMF.

Advantages:

Mild deprotection conditions (base-labile) — compatible with acid-labile side-chain protecting groups
Cleavage from resin uses TFA (relatively mild acid)
Compatible with automated peptide synthesizers
Wide range of available Fmoc-amino acid derivatives with diverse side-chain protection
Easier to monitor (Fmoc removal produces a UV-active byproduct — dibenzofulvene-piperidine adduct — that can be quantified spectrophotometrically to monitor coupling efficiency)

Boc (tert-Butyloxycarbonyl) Chemistry

Boc is the original Merrifield method. The Boc group is removed with TFA (acid), and final cleavage uses HF (hydrofluoric acid) — a highly toxic, corrosive reagent that requires specialized equipment.

Advantages:

Faster coupling kinetics for some sequences
Better for certain difficult sequences prone to aggregation
Lower cost for some applications

Disadvantages:

Requires hazardous HF for cleavage
Less compatible with automation
Largely superseded by Fmoc for routine synthesis

Common Synthesis Impurities

Understanding synthesis impurities helps in interpreting HPLC chromatograms and COAs:

Deletion Sequences

If a coupling reaction fails to go to completion (even at 99% efficiency, this means 1% of chains miss that amino acid), the resulting chains are missing one or more amino acids. These “deletion peptides” are the most common impurities in synthetic peptides.

For a 30-amino-acid peptide with 99% coupling efficiency per step:

Overall yield of correct sequence: 0.99^29 = 74.7%
25.3% of chains will have one or more deletions

This is why coupling efficiency is so critical — even small decreases in per-step efficiency compound dramatically over long sequences.

Truncated Sequences

If a coupling step fails completely (0% efficiency), all subsequent amino acids are added to a chain that is missing everything before the failure point. The result is a truncated peptide starting from the point of failure.

Racemization

During coupling, the alpha-carbon of the activated amino acid can undergo partial racemization (conversion of L-amino acid to D-amino acid). Racemization is sequence-dependent and particularly problematic for histidine and cysteine residues.

Side Reactions

Side Reaction	Cause	Affected Residues
Aspartimide formation	Acid/base-catalyzed cyclization	Asp-Gly, Asp-Ser, Asp-Thr sequences
Diketopiperazine (DKP)	Cyclization of first two residues	Pro at position 2
Oxidation	Air oxidation during cleavage	Met (→ Met sulfoxide), Cys, Trp
Deamidation	Hydrolysis of amide side chain	Asn, Gln
Alkylation	TFA cleavage byproducts	Trp, Cys, Met, Tyr

Difficult Sequences

Some peptide sequences are inherently challenging to synthesize:

Aggregation-Prone Sequences

Sequences rich in hydrophobic residues (Val, Ile, Leu, Phe) or containing beta-sheet-promoting motifs can aggregate on the resin during synthesis. Aggregation prevents the incoming amino acid from accessing the N-terminal amine, causing coupling failure.

Strategies to overcome aggregation:

Pseudoprolines: Temporary proline-like protecting groups that disrupt beta-sheet formation on resin
Backbone protection (Hmb, Dmb): Protecting groups on backbone amide nitrogens that prevent hydrogen bonding and aggregation
Microwave-assisted synthesis: Heat disrupts on-resin aggregation
Chaotropic additives: LiCl or LiBr added to the coupling solvent to disrupt secondary structure

Long Sequences (>40 amino acids)

The cumulative effect of imperfect coupling efficiency makes long peptides increasingly challenging. Strategies include:

Fragment condensation: Synthesize shorter fragments separately, then join them
Native chemical ligation: A chemoselective reaction that joins two unprotected peptide fragments at a cysteine residue
Recombinant expression: For very long peptides/small proteins, E. coli expression may be more practical than chemical synthesis

Purification Methods

Preparative HPLC

Reversed-phase HPLC is the standard purification method for synthetic peptides. The crude peptide mixture is separated on a C18 column using a water/acetonitrile gradient with TFA as the ion-pairing agent.

The target peptide elutes at a characteristic retention time, and fractions containing the pure peptide are collected, pooled, and lyophilized. Multiple HPLC runs may be needed to achieve the desired purity level.

Typical purity outcomes:

Crude peptide: 50-85% purity
Single HPLC purification: 90-98% purity
Multiple purifications or extended gradients: >98-99% purity

Ion Exchange Chromatography

Used for peptides where charge-based separation provides better resolution than hydrophobicity-based separation (reversed-phase HPLC). Particularly useful for separating peptides differing by a single charge (e.g., deamidated variants).

Size Exclusion Chromatography (SEC)

Separates by molecular size. Useful for removing aggregates and for separating peptide conjugates (PEGylated peptides, lipidated peptides) from unconjugated starting material.

Quality Control Analytics

After purification, the peptide undergoes quality control testing:

HPLC Purity

Analytical HPLC (distinct from preparative HPLC used for purification) quantifies purity by measuring the peak area of the target peptide relative to all detected peaks. This is the primary quality metric reported on a COA.

Mass Spectrometry (MS)

Confirms the molecular identity of the peptide. ESI-MS or MALDI-TOF MS measures the molecular weight, which must match the theoretical mass calculated from the amino acid sequence. Mass accuracy within ±1 Da (ESI) or ±0.1% (MALDI) confirms identity.

Amino Acid Analysis (AAA)

Quantifies the amino acid composition after acid hydrolysis. Confirms that the correct amino acids are present in the correct ratios and determines the net peptide content of the lyophilized powder.

Scale of Synthesis

Scale	Typical Amount	Common Use
Milligram (1-100 mg)	Research quantities	Academic research, screening
Gram (0.1-10 g)	Preclinical quantities	Animal studies, assay development
Multi-gram (10-100 g)	Clinical trial material	Phase I/II trials
Kilogram	Commercial production	Approved therapeutics

Research-grade peptides are typically manufactured at the milligram to gram scale. Manufacturing costs increase substantially with scale, purity requirements, and sequence complexity.

Frequently Asked Questions

Why does purity decrease for longer peptides?

Each coupling step has a finite efficiency (typically 99-99.9%). The overall yield of the correct, full-length sequence is the product of all individual coupling efficiencies: for a 40-residue peptide at 99.5% per-step efficiency, overall yield = 0.995^39 = 82.3%. For a 50-residue peptide: 0.995^49 = 78.1%. Longer peptides have more opportunities for coupling failures, deletions, and side reactions, all of which reduce the proportion of full-length, correct product.

What is the difference between crude and purified peptide?

Crude peptide is the raw product after cleavage from the resin — it contains the target sequence plus all synthesis impurities (deletions, truncations, side reaction products). Purified peptide has been separated from these impurities by preparative HPLC. Research-grade peptides should always be purified; crude peptides are not suitable for biological research.

Why do COAs report different purities for the same peptide?

Purity is batch-specific and depends on synthesis conditions, purification effort, and the inherent difficulty of the sequence. A well-optimized synthesis of a short, easy sequence (BPC-157, 15 amino acids) routinely achieves >98% purity. A challenging long sequence with difficult coupling positions may achieve only 95% even with extensive purification. Variation between lots is normal and expected — identical purities across all lots would be suspicious.

What does “TFA salt” vs. “acetate salt” mean?

TFA (trifluoroacetic acid) is used in HPLC purification as an ion-pairing agent. The purified peptide typically retains TFA as a counter-ion (TFA salt form). Some applications (cell culture, in vivo studies) are sensitive to TFA, so peptides can be converted to the acetate salt form by additional processing (ion exchange or repeated lyophilization from acetic acid). Acetate salt peptides are TFA-free but may have slightly different solubility properties.

How is peptide synthesis different from recombinant protein production?

Chemical synthesis (SPPS) builds peptides from individual amino acids using organic chemistry. Recombinant production uses living cells (typically E. coli) to express the peptide from a DNA template. SPPS is preferred for peptides under ~50 amino acids and for sequences containing non-natural amino acids, D-amino acids, or chemical modifications. Recombinant expression is preferred for larger proteins (>50-100 amino acids) and when natural post-translational modifications are needed.

References

Merrifield RB. “Solid phase peptide synthesis. I. The synthesis of a tetrapeptide.” J Am Chem Soc. 1963;85(14):2149-2154.
Amblard M, et al. “Methods and protocols of modern solid phase peptide synthesis.” Mol Biotechnol. 2006;33(3):239-254.
El-Faham A, Albericio F. “Peptide coupling reagents, more than a letter soup.” Chem Rev. 2011;111(11):6557-6602.
Coin I, et al. “Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences.” Nat Protocols. 2007;2(12):3247-3256.
Mueller LK, et al. “Challenges and perspectives in chemical synthesis of highly hydrophobic peptides.” Front Bioeng Biotechnol. 2020;8:162.
Palomo JM. “Solid-phase peptide synthesis: an overview focused on the preparation of biologically relevant peptides.” RSC Adv. 2014;4(62):32658-32672.
Isidro-Llobet A, et al. “Amino acid-protecting groups.” Chem Rev. 2009;109(6):2455-2504.
Dawson PE, et al. “Synthesis of proteins by native chemical ligation.” Science. 1994;266(5186):776-779.